Note 4 - Intangible Assets and Goodwill

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

NOTE 4 – INTANGIBLE ASSETS AND GOODWILL

The components of intangible assets were as follows:

	As of March 31, 2022							As of December 31, 2021
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Impairment			Net Carrying Amount
Patents & Trademarks	$	488,158	$	(236,595	)	$	251,563	$	453,314	$	(230,572	)	$	-		$	222,742
Developed Technology		3,500,000		(123,959	)		3,376,041		6,382,000		(432,733	)		(2,485,725	)		3,463,542
Customer Relationships		200,000		(7,083	)		192,917		645,000		(410,000	)		(37,083	)		197,917
Tradename		80,000		(7,083	)		72,917		478,000		(29,343	)		(370,740	)		77,917
Total	$	4,268,158	$	(374,720	)	$	3,893,438	$	7,958,314	$	(1,102,648	)	$	(2,893,548	)	$	3,962,118

The impairment loss recognized during the year ended December 31, 2021 adjusted the carrying amount of a long-lived asset. As a result, the gross carrying cost shown as of March 31, 2022 reflects the new cost basis per ASC 360-10-35-20. Amortization expense was $103,524 and $83,048 during the three months ended March 31, 2022 and 2021, respectively.

Goodwill

The goodwill, for our Helomics operating segment, was $0 at March 31, 2022 and December 31, 2021, and the cumulative impairment losses are $23,790,290. Goodwill for our zPREDICTA operating segment was $6,857,790 as of March 31, 2022 and December 31, 2021 with no cumulative impairment losses.